RxDoctor Payments Data

Inderpal Singh, MD

Cardiovascular Disease · Goshen, NYNPI 1104829738

Payments from drug & device makers

$172,893in general payments, 2019–2025

Across 501 payments — averaging $345.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$43K
  • Novartis$32K
  • Amgen$28K
  • AstraZeneca$24K
  • Johnson & Johnson$21K
  • Lilly USA, LLC$11K
  • plus $13K from 31 others

What the payments were for

  • Consulting fees$3000%
  • Speaking & faculty fees$148,96986%
  • Travel & lodging$10,6726%
  • Food & beverage$12,9257%
  • Education$280%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$172,893 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$755,789
Medicare patients
1,784
Services billed
6,612

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban610$821,272
EliquisApixaban576$737,075
EntrestoSacubitril/Valsartan391$606,236
JardianceEmpagliflozin175$247,556
Repatha SureclickEvolocumab215$162,396
FarxigaDapagliflozin Propanediol105$144,451
MultaqDronedarone Hcl73$141,291
Praluent PenAlirocumab68$43,285
Ezetimibe849$27,953
Rosuvastatin Calcium1,407$24,999
BrilintaTicagrelor18$22,648
Valsartan627$19,684
Atorvastatin Calcium1,561$19,516
NexlizetBempedoic Acid/Ezetimibe17$19,237
Metoprolol Succinate1,129$17,985

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$20,810$821,272610 claims
PfizerEliquis$123$737,075576 claims
NovartisEntresto$32,164$606,236391 claims
Boehringer IngelheimJardiance, Pradaxa$43,318$252,813192 claims
AstraZenecaFarxiga, Brilinta$24,247$167,099123 claims
Sanofi-aventis U.S. LLCMultaq$57$141,29173 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$139$31,03528 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Goshen

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →